Le Lézard
Classified in: Health
Subject: LAW

More Bad News For Allergan plc.: Prescriber's Choice Inc. and Sincerus Florida, LLC File Suit Against Allergan For Unfair Trade Practices


POMPANO BEACH, Fla., Oct. 12, 2017 /PRNewswire/ -- Prescriber's Choice Inc. and Sincerus Florida LLC -- two companies that are revolutionizing the way that pharmaceutical drugs are dispensed -- announced that they have filed counterclaims in their lawsuit against the Bio-pharma giant Allergan plc.  The counterclaim alleges that Allergan representatives use false and misleading tactics to dissuade prescribers from working with the two companies, which facilitate physician dispensing of customized lower cost alternatives.  The counterclaim comes at a time when Allergan is already under fire for the ethics of their business conduct.

Commenting on the lawsuit, the companies issued the following statement:

"Prescriber's Choice and Sincerus Florida are saddened that a Biopharmaceutical company as large as Allergan must resort to using unscrupulous tactics to mislead prescribers.  Rather than relying on the strength of their branded products, they have resorted to telling lies and using bully tactics to instill uncertainty and fear. Today, in true David vs Goliath fashion, we have fired back at the giant by bringing suit against them.  Prescriber's Choice and Sincerus Florida have an altruistic vision to provide access to customized affordable medications.  This suit is another step in the fight to bring safe innovation to doctors, patients, and the healthcare system."

About Prescriber's Choice Inc and Sincerus Florida, LLC

Prescriber's Choice Inc. and Sincerus Florida LLC are two companies working together to change the paradigm of drug dispensing.  Prescriber's Choice which serves as a marketing and consulting arm for Sincerus Florida, a FDA Registered 503B Outsourcing Facility, both work with prescribers to create their own customized formulary, dispense the personalized medications at the time of the patient visit, and allow patients affordable access to drugs.  Most of the time, the customized drugs that are dispensed are less than the patients' copayment at the pharmacy on a commercially available drug.

Prescriber's Choice and Sincerus Florida are paving the way for a more streamlined access to medications.  Thousands of prescribers around the nation have implemented this streamlined approach.  The goals of Prescriber's Choice and Sincerus Florida are to help prescribers so that they can enhance their patients' understanding, increase their patients' compliance, and improve their patients' outcomes.

Contacts:
[email protected]

SOURCE Prescriber's Choice


These press releases may also interest you

at 10:38
Neurent Medical, a company pioneering innovative non-surgical interventions to treat chronic inflammatory sinonasal diseases, today announced the appointment of Mr. John Peterson as the new Vice President of Sales & Marketing, effective immediately....

at 10:30
Endoscopy Equipment Market in terms of revenue was estimated to be worth $32.3 billion in 2024 and is poised to reach $46.2 billion by 2029, growing at a CAGR of 7.4% from 2024 to 2029 according to a new report by MarketsandMarketstm. The growth in...

at 10:29
Integrity Marketing Group, LLC ("Integrity"), one of the leading independent distributors of life, health and wealth products, today announced that Integrity Co-Founder and CEO Bryan W. Adams has been recognized as a top CEO for large companies in...

at 10:28
On March 28, 2024, Broncus Medical (02216.HK) (the "Company" or "we" ) announced annual results for FY 2023. In 2023, Broncus Medical earned product sales of US$12.41 million, an increase of 32% compared to the previous year. Of which, total revenue...

at 10:28
In a groundbreaking leap forward in the realm of nutrition and fitness technology, Portions Master announces the launch of its revolutionary app, set to transform the way individuals approach portion control and nutritional tracking....

at 10:21
Highlights of the Annual Results as of December 31, 2023: Revenue reached RMB2,155.6 millionGross profit amounted to RMB738.5 millionAdjusted non-IFRS net loss improved to RMB208.8 million, representing a significant turnaround from a negative...



News published on and distributed by: